A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Protoporphyrins Fractionated, Whole Blood
MessageDue to specimen stability, samples should be drawn MONDAY through THURSDAY before 1430EST only, and not the day before a holiday.
*Keep specimen on ice and transport to processing ASAP.
Patient should abstain from alcohol for 24 hours prior to specimen collection.
*Keep specimen on ice and transport to processing ASAP.
Patient should abstain from alcohol for 24 hours prior to specimen collection.
Test Code
LAB00283
Alias/See Also
LAB00283
Mayo TC: PPFE
Erythropoietic Protoporphyrins Fractionated (EPP)
Mayo TC: PPFE
Erythropoietic Protoporphyrins Fractionated (EPP)
CPT Codes
82542
Preferred Specimen
4.0 mL Dark Green Top (Sodium Heparin) - Whole Blood
Minimum Volume
3.0 mL Dark Green Top (Sodium Heparin) - Whole Blood
Other Acceptable Specimens
Lavender (EDTA) - Whole Blood
Transport Container
Dark Green top. Place sample on wet ice immediately after collection. Transport to lab ASAP.
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated: 7 days
Methodology
Extraction followed by fractionation by high-performance liquid chromatography. Zinc protoporphyrin and free protoporphyrin are separately quantitated.
Report Available
3-5 days
Limitations
Patients must abstain from alcohol for at least 24 hours prior to speicmen collection. Alcohol suppresses enzyme activity potentially leading to false-positive results.
Reference Range
FREE PROTOPORPHYRIN
<20 mcg/dL
ZINC-COMPLEXED PROTOPORPHYRIN
<60 mcg/dL
Abnormal results are reported with a detailed interpretation that may include an overview of the resutls and their significance, a correlation to available clinical information provided with the specimen, differential diagnosis, and recommendations for additional testing when indicated and available.
<20 mcg/dL
ZINC-COMPLEXED PROTOPORPHYRIN
<60 mcg/dL
Abnormal results are reported with a detailed interpretation that may include an overview of the resutls and their significance, a correlation to available clinical information provided with the specimen, differential diagnosis, and recommendations for additional testing when indicated and available.
Clinical Significance
Evaluating patients with possible diagnosis of erythropoietic protoporphyria or X-linked dominant portoporphyria.
Establishing a biochemical diagnosis of erythropoietic protoporphyria and X-linked dominant protoporphyria.
Establishing a biochemical diagnosis of erythropoietic protoporphyria and X-linked dominant protoporphyria.
Performing Laboratory
Mayo Clinic Laboratories